Jump to main content
Jump to site search

Issue 57, 2018
Previous Article Next Article

An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization

Author affiliations

Abstract

An azobenzene-based heteromeric prodrug (hNDP) was prepared for targeted chemotherapy against hypoxic tumor. hNDP could divert the parent drug from nucleus to cytoplasm with lower toxicity, while the azoreduction of hNDP in hypoxia would activate the drug with a robust anti-tumor effect by initiating the apoptosis-related biochemical cascades.

Graphical abstract: An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 Apr 2018, accepted on 19 Jun 2018 and first published on 20 Jun 2018


Article type: Communication
DOI: 10.1039/C8CC03430C
Citation: Chem. Commun., 2018,54, 7983-7986
  •   Request permissions

    An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization

    S. Li, X. Jiang, R. Zheng, S. Zuo, L. Zhao, G. Fan, J. Fan, Y. Liao, X. Yu and H. Cheng, Chem. Commun., 2018, 54, 7983
    DOI: 10.1039/C8CC03430C

Search articles by author

Spotlight

Advertisements